Eascra Biotech

Executive Summary

Eascra Biotech is a Boston-based nanomedicine company pioneering Janus base nanoparticles (JBNps), a DNA-inspired synthetic molecule that fully encapsulates therapeutic cargoes (siRNA, mRNA, Cas9, proteins) for delivery to hard-to-penetrate tissues such as articular cartilage, kidneys, and ECM-rich solid tumors. Unlike lipid nanoparticles, JBNps enable room-temperature stability and prolonged bioactivity, addressing key challenges in drug delivery. Founded in 2020, the company operates at an early preclinical stage, with no disclosed funding or partnerships. Its proprietary platform holds promise for expanding the druggable space in diseases where current delivery systems are ineffective, though validation in vivo remains critical. Eascra represents a high-risk, high-reward opportunity in the drug delivery space, with potential to disrupt the field if JBNps demonstrate safety and efficacy in preclinical models.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing60% success
• Q1 2027Preclinical Proof-of-Concept Data in Cartilage or Renal Disease Models50% success
• Q2 2027Collaboration/Partnership with Major Pharma for ECM-Rich Tumor Delivery30% success